Person

Back to overview

Schibli Roger

Gender Male
Institute Paul Scherrer Institut
ORCID 0000-0002-1537-3833
Show all

Projects as responsible applicant

Responsible applicant Institution of higher education Start End date Funding scheme

Novel enzymatic methods for the site-specific modification of therapeutic proteins
Schibli Roger ETH Zurich - ETHZ 01.05.2008 30.04.2010 Project funding (Div. I-III)

Novel enzymatic methods for the site-specific modification of therapeutic proteins
Schibli Roger ETH Zurich - ETHZ 01.05.2006 30.04.2008 Project funding (Div. I-III)

MobiPET: A mobile, small animal PET scanner for molecular imaging
Schibli Roger ETH Zurich - ETHZ 01.03.2015 29.02.2016 R'EQUIP

Translational molecular imaging of neuroendocrine tumours using innovative PET radionuclides
Schibli Roger Paul Scherrer Institute - PSI 01.04.2015 31.03.2019 India

Novel routes to 18F-labelled amino acids and vitamin derivatives useful for non-invasive, nuclear imaging of oncological and neurodegenerative diseases
Schibli Roger ETH Zurich - ETHZ 01.05.2014 30.04.2016 SCOPES

Targeted polymers for site-specific drug delivery
Schibli Roger Paul Scherrer Institute - PSI 01.03.2010 29.02.2012 SCOPES

Improving the Efficacy and Quality of Immunoconjugates Using Novel Enzymatic Methods for the Site-specific and Stoichiometric Modification of Proteins
Schibli Roger Paul Scherrer Institute - PSI 01.04.2011 31.03.2014 Project funding (Div. I-III)

Projects as co-applicant

Responsible applicant Institution of higher education Start End date Funding scheme

Novel Imaging and Therapeutic Tools in Systemic Sclerosis
Distler Oliver University of Zurich - ZH 01.01.2015 31.12.2018 Sinergia

Development of New Folate-Based RadioImaging Agents and RadioTherapeutics
Müller Cristina Paul Scherrer Institute - PSI 01.04.2015 31.07.2018 Project funding (Div. I-III)

Development of a Radioligand for ACE2 PET Imaging - A Tool to Investigate the Expression and Regulation of the SARS-CoV-2 Entry Receptor
Müller Cristina Paul Scherrer Institute - PSI 01.10.2020 30.09.2022 NRP 78 Covid-19

SAFIR - From the Prototype to the Full-Scale Scanner
Dissertori Günther ETH Zurich - ETHZ 01.09.2020 31.12.2022 R'EQUIP

Combined beta- and Auger electron therapy using a novel somatostatin receptor subtype 2 antagonist labelled with terbium-161 (161Tb-DOTA-LM3) - a phase 0/ phase I study
Wild Damian University of Basel - BS 01.01.2022 31.12.2025 Project funding (Div. I-III)

Projects as project partner

Responsible applicant Institution of higher education Start End date Funding scheme

Imaging Mitochondrial Dysfunction in Neurodegenerative and Cardiovascular Diseases by Targeting the Alpha Subunit of ATP Synthase (ATP5A)
Mu Linjing ETH Zurich - ETHZ 01.03.2021 28.02.2025 Project funding (Div. I-III)

Investigation of a New Class of Folate-Based RadioImaging Agents and RadioTherapeutics
Müller Cristina Paul Scherrer Institute - PSI 01.02.2020 31.01.2024 Project funding (Div. I-III)

Development of Novel Exotic Radionuclides Towards Preclinical and Clinical Medical Applications
van der Meulen Nicholas Paul Scherrer Institute - PSI 01.02.2020 31.01.2024 Project funding (Div. I-III)

Brain Imaging of the Glutamatergic System: First-in-man Evaluation of a Novel 18F-PET Radioligand Targeting mGlu5 in Caucasian and Asian subjects and the Development of a PET Ligand for Imaging Glutamatergic GluN2A Receptor Subtype
Ametamey Simon M. ETH Zurich - ETHZ 01.03.2016 31.08.2020 South Korea

-